Your browser doesn't support javascript.
loading
PINK1-dependent and Parkin-independent mitophagy is involved in reprogramming of glycometabolism in pancreatic cancer cells.
Miyazaki, Natsumi; Shiratori, Reika; Oshima, Taichi; Zhang, Zhiheng; Valencia, Robert; Kranrod, Joshua; Fang, Liye; Seubert, John M; Ito, Kousei; Aoki, Shigeki.
Affiliation
  • Miyazaki N; Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan.
  • Shiratori R; Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan.
  • Oshima T; Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan.
  • Zhang Z; Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan.
  • Valencia R; Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
  • Kranrod J; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
  • Fang L; Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
  • Seubert JM; Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
  • Ito K; Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan.
  • Aoki S; Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan. Electronic address: aokishigeki@chiba-u.jp.
Biochem Biophys Res Commun ; 625: 167-173, 2022 10 15.
Article in En | MEDLINE | ID: mdl-35963163
Cancer cells rely on glycolysis to generate ATP for survival. However, inhibiting glycolysis is insufficient for the eradication of cancer cells because glycolysis-suppressed cells undergo metabolic reprogramming toward mitochondrial oxidative phosphorylation. We previously described that upon glycolytic suppression in pancreatic cancer cells, intracellular glycometabolism is shifted toward mitochondrial oxidative phosphorylation in an autophagy-dependent manner for cellular survival. Here, we hypothesized that mitophagy, which selectively degrades mitochondria via autophagy, is involved in mitochondrial activation under metabolic reprogramming. We revealed that glycolytic suppression notably increased mitochondrial membrane potential and mitophagy in a pancreatic cancer cell model (PANC-1). PTEN-induced kinase 1 (PINK1), a ubiquitin kinase that regulates mitophagy in healthy cells, regulated mitochondrial activation through mitophagy by glycolytic suppression. However, Parkin, a ubiquitin ligase regulated by PINK1 in healthy cells to induce mitophagy, was not involved in the PINK1-dependent mitophagy of the cancer glycometabolism. These results imply that cancer cells and healthy cells have different regulatory pieces of machinery for mitophagy, and inhibition of cancer-specific mechanisms may be a potential strategy for cancer therapy targeting metabolic reprogramming.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Protein Kinases / Mitophagy Type of study: Prognostic_studies Limits: Humans Language: En Journal: Biochem Biophys Res Commun Year: 2022 Type: Article Affiliation country: Japan

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Protein Kinases / Mitophagy Type of study: Prognostic_studies Limits: Humans Language: En Journal: Biochem Biophys Res Commun Year: 2022 Type: Article Affiliation country: Japan